WallStreetZenWallStreetZen

NASDAQ: NMTC
Neuroone Medical Technologies Corp Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

NMTC past revenue growth

How has NMTC's revenue growth performed historically?
Company
1,827.66%
Industry
7.33%
Market
21.8%
NMTC's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
NMTC's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
NMTC's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

NMTC earnings and revenue history

Current Revenue
$3.6M
Current Earnings
-$8.9M
Current Profit Margin
-244.5%

NMTC Return on Equity

Current Company
-86%
Current Industry
8.7%
Current Market
188.7%
NMTC's Return on Equity (-86%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when NMTC announces earnings.

NMTC Return on Assets

Current Company
-74.2%
Current Industry
5%
NMTC is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

NMTC Return on Capital Employed

Current Company
-107.2%
Current Industry
8.4%
NMTC's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

NMTC vs Medical Device Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
NMTC$3.65M-$8.69M-$8.92M+34.41%N/A
LNSR$35.36M-$15.99M-$19.91M+9.73%N/A
VAPO$66.80M-$94.30M-$113.26M+13.42%N/A
ICUN/AN/AN/AN/AN/A
OSA$0.00N/A-$232.07kN/AN/A
View Top Medical Device Stocks

NMTC earnings dates

Next earnings date
May 10, 2023

Neuroone Medical Technologies Earnings & Revenue FAQ

What were NMTC's earnings last quarter?

On Invalid Date, Neuroone Medical Technologies (NASDAQ: NMTC) reported Q4 2022 earnings per share (EPS) of -$0.11, up 38.89% year over year. Total Neuroone Medical Technologies earnings for the quarter were -$1.73 million. In the same quarter last year, Neuroone Medical Technologies's earnings per share (EPS) was -$0.18.

If you're new to stock investing, here's how to buy Neuroone Medical Technologies stock.

What was NMTC's earnings growth in the past year?

As of Q1 2023, Neuroone Medical Technologies's earnings has grown year over year. Neuroone Medical Technologies's earnings in the past year totalled -$8.92 million.

What is NMTC's earnings date?

Neuroone Medical Technologies's earnings date is Invalid Date. Add NMTC to your watchlist to be reminded of NMTC's next earnings announcement.

What was NMTC's revenue last quarter?

On Invalid Date, Neuroone Medical Technologies (NASDAQ: NMTC) reported Q4 2022 revenue of $1.57 million up 3,812.48% year over year. In the same quarter last year, Neuroone Medical Technologies's revenue was $40.12 thousand.

What was NMTC's revenue growth in the past year?

As of Q1 2023, Neuroone Medical Technologies's revenue has grown 1,827.66% year over year. This is 1,820.33 percentage points higher than the US Medical Devices industry revenue growth rate of 7.33%. Neuroone Medical Technologies's revenue in the past year totalled $3.65 million.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.